MedTrace Logo

BREMEN Eye Drops Versus Combigan for Open-angle Glaucoma or Intraocular Hypertension

NCT03235232 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 406

Last updated 2024-02-20

No results posted yet for this study

Summary

The purpose of this study is to evaluate the clinical efficacy of the BREMEN eye drops in the treatment of primary open-angle glaucoma or intraocular hypertension.

Conditions

Interventions

DRUG

BREMEN eye drops

1 drop in the affected eye(s), twice a day (approximately each 12 hours) for 8 weeks.

DRUG

Combigan®

1 drop of Combigan® in the affected eye(s), twice a day (approximately each 12 hours) for 8 weeks.

Sponsors & Collaborators

  • EMS

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2023-07-31
Completion
2023-10-31

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03235232 on ClinicalTrials.gov